Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories
15th National Conference of the IAOMFP, Chennai, 2006
Abstract
Abstracts from current literature
Acne in India: Guidelines for management - IAA Consensus Document
Addendum
Announcement
Art & Psychiatry
Article
Articles
Association Activities
Association Notes
Award Article
Book Review
Brief Report
Case Analysis
Case Letter
Case Letters
Case Notes
Case Report
Case Reports
Clinical and Laboratory Investigations
Clinical Article
Clinical Studies
Clinical Study
Commentary
Conference Oration
Conference Summary
Continuing Medical Education
Correspondence
Corrigendum
Cosmetic Dermatology
Cosmetology
Current Best Evidence
Current View
Derma Quest
Dermato Surgery
Dermatopathology
Dermatosurgery Specials
Dispensing Pearl
Do you know?
Drug Dialogues
e-IJDVL
Editor Speaks
Editorial
Editorial Remarks
Editorial Report
Editorial Report - 2007
Editorial report for 2004-2005
Errata
Erratum
Focus
Fourth All India Conference Programme
From Our Book Shelf
From the Desk of Chief Editor
General
Get Set for Net
Get set for the net
Guest Article
Guest Editorial
History
How I Manage?
IADVL Announcement
IADVL Announcements
IJDVL Awards
IJDVL AWARDS 2015
IJDVL Awards 2018
IJDVL Awards 2019
IJDVL Awards 2020
IJDVL International Awards 2018
Images in Clinical Practice
In Memorium
Inaugural Address
Index
Knowledge From World Contemporaries
Leprosy Section
Letter in Response to Previous Publication
Letter to Editor
Letter to the Editor
Letter to the Editor - Case Letter
Letter to the Editor - Letter in Response to Published Article
LETTER TO THE EDITOR - LETTERS IN RESPONSE TO PUBLISHED ARTICLES
Letter to the Editor - Observation Letter
Letter to the Editor - Study Letter
Letter to the Editor - Therapy Letter
Letter to the Editor: Articles in Response to Previously Published Articles
Letters in Response to Previous Publication
Letters to the Editor
Letters to the Editor - Letter in Response to Previously Published Articles
Letters to the Editor: Case Letters
Letters to the Editor: Letters in Response to Previously Published Articles
Medicolegal Window
Messages
Miscellaneous Letter
Musings
Net Case
Net case report
Net Image
Net Letter
Net Quiz
Net Study
New Preparations
News
News & Views
Obituary
Observation Letter
Observation Letters
Oration
Original Article
ORIGINAL CONTRIBUTION
Original Contributions
Pattern of Skin Diseases
Pearls
Pediatric Dermatology
Pediatric Rounds
Perspective
Presedential Address
Presidential Address
Presidents Remarks
Quiz
Recommendations
Regret
Report
Report of chief editor
Report of Hon : Treasurer IADVL
Report of Hon. General Secretary IADVL
Research Methdology
Research Methodology
Resident page
Resident's Page
Resident’s Page
Residents' Corner
Residents' Corner
Residents' Page
Retraction
Review
Review Article
Review Articles
Revision Corner
Self Assessment Programme
SEMINAR
Seminar: Chronic Arsenicosis in India
Seminar: HIV Infection
Short Communication
Short Communications
Short Report
Special Article
Specialty Interface
Studies
Study Letter
Supplement-Photoprotection
Supplement-Psoriasis
Symposium - Contact Dermatitis
Symposium - Lasers
Symposium - Pediatric Dermatoses
Symposium - Psoriasis
Symposium - Vesicobullous Disorders
SYMPOSIUM - VITILIGO
Symposium Aesthetic Surgery
Symposium Dermatopathology
Symposium-Hair Disorders
Symposium-Nails Part I
Symposium-Nails-Part II
Systematic Reviews and Meta-analysis
Tables
Technology
Therapeutic Guidelines
Therapeutic Guidelines - IADVL
Therapeutics
Therapy
Therapy Letter
View Point
Viewpoint
What’s new in Dermatology
View/Download PDF
Letter to the Editor
2015:81:3;311-313
doi: 10.4103/0378-6323.155567
PMID: 25900936

Cutaneous involvement of marginal zone B-lymphoma noted after topical imiquimod; more than a coincidence?

Tamara Gracia-Cazaa1 , Anastasia Auls-Leonardo2 , Miguel ngel Marigil-Gmez3 , Yolanda Gilaberte4
1 Dermatology Service, Hospital Clinico Lozano Blesa, Zaragoza, Spain
2 Hematology Service, Hospital San Jorge, Huesca, Spain
3 Pathology Service, Hospital San Jorge, Huesca, Spain
4 Dermatology Service, Hospital San Jorge, Huesca, Spain

Correspondence Address:
Tamara Gracia-Cazaa
Department of Dermatology, Hospital Clnico Universitario "Lozano Blesa", Zaragoza. Street San Juan Bosco 15, P.O.Box: 50009 - Zaragoza
Spain
How to cite this article:
Gracia-Cazaa T, Auls-Leonardo A, Marigil-Gmez M, Gilaberte Y. Cutaneous involvement of marginal zone B-lymphoma noted after topical imiquimod; more than a coincidence?. Indian J Dermatol Venereol Leprol 2015;81:311-313
Copyright: (C)2015 Indian Journal of Dermatology, Venereology, and Leprology

Sir,

Topical imiquimod is a toll-like receptor (TLR) 7/8 agonist approved for the treatment of non-melanoma skin cancer (NMSC). Its side effects are usually local and less frequently systemic. [1] We report a case of secondary marginal zone B-lymphoma (MZL) that involved the areas where topical imiquimod was applied to treat actinic keratoses and superficial basal cell carcinomas.

An 84-year-old male presented with persistent superficial basal cell carcinomas (BCC) and actinic keratosis (AK) on both cheeks [Figure - 1]. These were previously treated with surgery and methyl-aminolevulinate photodynamic therapy (MAL-PDT). However, since some lesions were not responding to photodynamic therapy, it was decided to try topical imiquimod in order to avoid another surgical procedure. Six weeks after initiating the treatment, the patient developed erythematous and edematous plaques on both cheeks [Figure - 2]. There was associated cervical lymphadenopathy. Skin biopsy showed aggregates of small and medium sized lymphocytes with some plasma cells occupying the whole dermis; there was neither formation of germinal centers nor evidence of epidermotropism [Figure - 3]. The immunohistochemical study was strongly positive for CD20 [Figure - 2], CD79a, BCL2 and light chain restriction, with decreased expression of CD3, CD4, CD 123 and UCH L1, and negative for CD8, CD5 and CD10.

Figure 1: Basal cell carcinoma on the right temple and multiple actinic keratoses on left cheek, before imiquimod application
Figure 2: Erythematous and edematous plaques on both cheeks which appeared after topical application of imiquimod
Figure 3: Small and medium size lymphocytes diffusely infiltrate the entire dermis. (H and E, CD20, ×50). Inset - immunohistochemical staining for CD 20 was positive

Immunophenotyping of peripherial blood revealed that 38% of B lymphocytes had a marginal zone immunophenotype and 14% of bone marrow lymphocytes presented with a condensed chromatin pattern and small nucleoli. Upper gastrointestinal endoscopy was normal. Thoracic, abdominal and pelvic computed tomography showed a small, 7 mm nodule lower lobe of the right lung. The patient and his family declined further invasive tests. Considering all these findings, and in accordance with the definition of the WHO-EORTC, [2] we made the diagnosis of non-cutaneous (nodal or extranodal) marginal zone lymphoma with skin involvement, probably triggered by imiquimod. The patient was treated with rituximab (375 mg/m 2 ) and bendamustine (90 mg/m 2 ) weekly for the first four doses and then monthly with partial resolution of the skin lesions.

Cutaneous marginal zone lymphoma (CMZL) may be a primary cutaneous condition or the result of secondary involvement from non-cutaneous disease. Primary cutaneous marginal zone lymphoma is a very indolent lymphoma, which mostly affects young adults, with a distribution favoring the trunk and extremities. However, patients with secondary cutaneous marginal zone lymphoma are often older and the lesions are usually located on the head and neck. Cases of marginal zone lymphoma secondarily involving the skin can be histologically and immunophenotypically indistinguishable from primary cutaneous disease. [3]

The association between chronic antigenic stimulation and the microenvironment has been frequently reported in this type of lymphoma. The infectious agents most frequently associated with mucosa-associated lymphoid tissue (MALT) lymphoproliferations are Helicobacter pylori, Helicobacter heilmannii, hepatitis C virus, Campylobacter jejuni, Borrelia burgdorferi, and Chlamydia psittaci. These etiologic associations have led to the hypothesis that chronic or repeated immune stimulation leads to a lymphoid expansion which, in the presence of specific micro environmental factors and a genetic predisposition, can culminate in a malignant clone. [4] In primary cutaneous marginal zone lymphoma, the relationship with B. burgdorferi infection is the most frequently reported. Recently, Guitart et al. [5] also identified an association with gastrointestinal disorders, certain autoimmune conditions and some systemic malignant neoplasms indicating in some patients a possible local trigger event.

We found a single previous report of reactivation of Burkitt lymphoma after the use of imiquimod. [6] Imiquimod induces in vitro the production of cytokines such as TNF-α, IL-1, IL-6, IL-8, and IL-12 by monocytes, macrophages, and plasmocytoid dendritic cells through TLR 7/8 activation. The release of IL-12 itself promotes the production of IFN-γ by CD4 T lymphocytes which stimulates CD8 T lymphocytes, responsible for the death of tumoral and virus-infected cells. [1]

Toll like receptors are a part of the innate immune system that have been shown to recognize bacterial ligands and some autoantigens which results in the activation of pro-inflammatory cytokines and chemokines. Toll like receptors also influence apoptosis and cell proliferation. Imiquimod acts via toll like receptors and the inflammatory microenvironment caused by the drug is similar to that reported by Adam et al., [7] in extranodal lymphomas. They concluded that since gastric extranodal marginal zone B-cell lymphomas of MALT type exclusively express TLR 4 in contrast to other lymphomas infiltrating the stomach, the pattern of TLR expression correlates well with the putative model of lymphomagenesis and progression; this pattern of TLR expression resembles that produced by imiquimod.

Our hypothesis is that the inflammatory microenvironment induced by topical imiquimod could have triggered the involvement of marginal zone lymphoma in the treated areas. However, even though the lymphoma lesions appeared during treatment with imiquimod and there is lack of evidence of any association between methyl-aminolevulinate photodynamic therapy (MAL-PDT) and lymphoma development, a possible synergistic action between photodynamic therapy and imiquimod cannot be ruled out.

References
1.
Gaspari A, Tyring SK, Rosen T. Beyond a decade of 5% imiquimod topical therapy. J Drugs Dermatol 2009;8:467-74.
[Google Scholar]
2.
Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005;105:3768-85.
[Google Scholar]
3.
Gerami P, Wickless SC, Querfeld C, Rosen ST, Kuzel TM, Guitart J. Cutaneous involvement with marginal zone lymphoma. J Am Acad Dermatol 2010;63:142-5.
[Google Scholar]
4.
Pereira MI, Medeiros JA. Role of Helicobacter pylori in gastric mucosa-associated lymphoid tissue lymphomas. World J Gastroenterol 2014;20:684-98.
[Google Scholar]
5.
Guitart J, Deonizio J, Bloom T, Martinez-Escala ME, Kuzel TM, Gerami P, et al. High Incidence of Gastrointestinal Tract Disorders and Autoimmunity in Primary Cutaneous Marginal Zone B-Cell Lymphomas. JAMA Dermatol 2014;150:412-8.
[Google Scholar]
6.
Anadkat MJ, Bogucki BA. Development of adenopathy during the use of topical imiquimod. J Am Acad Dermatol 2011;64:e75-7.
[Google Scholar]
7.
Adam P, Schmausser B, Göbeler-Kolve M, Müller-Hermelink HK, Eck M. Gastric extranodal marginal zone B-cell lymphomas of MALT type exclusively express Toll-like receptor 4 in contrast to other lymphomas infiltrating the stomach. Ann Oncol 2008;19:566-9.
[Google Scholar]

Fulltext Views
270

PDF downloads
245
Show Sections